Tags

Type your tag names separated by a space and hit enter

Rationale for vaccination with trivalent or quadrivalent live attenuated influenza vaccines: Protective vaccine efficacy in the ferret model.
PLoS One 2018; 13(12):e0208028Plos

Abstract

BACKGROUND AND AIM

The majority of seasonal influenza vaccines are trivalent, containing two A virus strains (H1N1 and H3N2) and one B virus strain. The co-circulation of two distinct lineages of B viruses can lead to mismatch between the influenza B virus strain recommended for the trivalent seasonal vaccine and the circulating B virus. This has led some manufacturers to produce quadrivalent influenza vaccines containing one strain from each B lineage in addition to H1N1 and H3N2 strains. However, it is also important to know whether vaccines containing a single influenza B strain can provide cross-protectivity against viruses of the antigenically distinct lineage. The aim of this study was to assess in naïve ferrets the potential cross-protective activity of trivalent live attenuated influenza vaccine (T-LAIV) against challenge with a heterologous wild-type influenza B virus belonging to the genetically different lineage and to compare this activity with effectiveness of quadrivalent LAIV (Q-LAIV) in the ferret model.

METHODS AND RESULTS

Ferrets were vaccinated with either one dose of trivalent LAIV containing B/Victoria or B/Yamagata lineage virus, or quadrivalent LAIV (containing both B lineages), or placebo. They were then challenged with B/Victoria or B/Yamagata lineage wild-type virus 28 days after vaccination. The ferrets were monitored for clinical signs and morbidity. Nasal swabs and lung tissue samples were analyzed for the presence of challenge virus. Antibody response to vaccination was assessed by routine hemagglutination inhibition assay. All LAIVs tested were found to be safe and effective against wild-type influenza B viruses based on clinical signs, and virological and histological data. The absence of interference between vaccine strains in trivalent and quadrivalent vaccine formulations was confirmed. Trivalent LAIVs were shown to have the potential to be cross-protective against infection with genetically different influenza B/Victoria and B/Yamagata lineages.

CONCLUSIONS

In this ferret model, quadrivalent vaccine provided higher protection to challenge against both B/Victoria and B/Yamagata lineage viruses. However, T-LAIV provided some cross-protection in the case of a mismatch between circulating and vaccine type B strains. Notably, B/Victoria-based T-LAIV was more protective compared to B/Yamagata-based T-LAIV.

Authors+Show Affiliations

Department of Virology, Institute of Experimental Medicine, St Petersburg, Russia.Department of Virology, Institute of Experimental Medicine, St Petersburg, Russia.Department of Virology, Institute of Experimental Medicine, St Petersburg, Russia.Department of Virology, Institute of Experimental Medicine, St Petersburg, Russia.Department of Virology, Institute of Experimental Medicine, St Petersburg, Russia.Department of Virology, Institute of Experimental Medicine, St Petersburg, Russia.Department of Virology, Institute of Experimental Medicine, St Petersburg, Russia.Department of Virology, Institute of Experimental Medicine, St Petersburg, Russia.Department of Toxicology and Microbiology, Institute of Preclinical Research Ltd, St Petersburg, Russia.Department of Toxicology and Microbiology, Institute of Preclinical Research Ltd, St Petersburg, Russia.Department of Toxicology and Microbiology, Institute of Preclinical Research Ltd, St Petersburg, Russia.Universal Health Coverage and Health Systems, World Health Organization, Geneva, Switzerland.Universal Health Coverage and Health Systems, World Health Organization, Geneva, Switzerland.International Institutional Cooperation, Institut national de la santé et de la recherche médicale (INSERM), Paris, France.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

30507951

Citation

Rudenko, Larisa, et al. "Rationale for Vaccination With Trivalent or Quadrivalent Live Attenuated Influenza Vaccines: Protective Vaccine Efficacy in the Ferret Model." PloS One, vol. 13, no. 12, 2018, pp. e0208028.
Rudenko L, Kiseleva I, Krutikova E, et al. Rationale for vaccination with trivalent or quadrivalent live attenuated influenza vaccines: Protective vaccine efficacy in the ferret model. PLoS ONE. 2018;13(12):e0208028.
Rudenko, L., Kiseleva, I., Krutikova, E., Stepanova, E., Rekstin, A., Donina, S., ... Kieny, M. P. (2018). Rationale for vaccination with trivalent or quadrivalent live attenuated influenza vaccines: Protective vaccine efficacy in the ferret model. PloS One, 13(12), pp. e0208028. doi:10.1371/journal.pone.0208028.
Rudenko L, et al. Rationale for Vaccination With Trivalent or Quadrivalent Live Attenuated Influenza Vaccines: Protective Vaccine Efficacy in the Ferret Model. PLoS ONE. 2018;13(12):e0208028. PubMed PMID: 30507951.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Rationale for vaccination with trivalent or quadrivalent live attenuated influenza vaccines: Protective vaccine efficacy in the ferret model. AU - Rudenko,Larisa, AU - Kiseleva,Irina, AU - Krutikova,Elena, AU - Stepanova,Ekaterina, AU - Rekstin,Andrey, AU - Donina,Svetlana, AU - Pisareva,Maria, AU - Grigorieva,Elena, AU - Kryshen,Kirill, AU - Muzhikyan,Arman, AU - Makarova,Marina, AU - Sparrow,Erin Grace, AU - Torelli,Guido, AU - Kieny,Marie-Paule, Y1 - 2018/12/03/ PY - 2018/06/15/received PY - 2018/11/10/accepted PY - 2018/12/4/entrez PY - 2018/12/7/pubmed PY - 2019/5/23/medline SP - e0208028 EP - e0208028 JF - PloS one JO - PLoS ONE VL - 13 IS - 12 N2 - BACKGROUND AND AIM: The majority of seasonal influenza vaccines are trivalent, containing two A virus strains (H1N1 and H3N2) and one B virus strain. The co-circulation of two distinct lineages of B viruses can lead to mismatch between the influenza B virus strain recommended for the trivalent seasonal vaccine and the circulating B virus. This has led some manufacturers to produce quadrivalent influenza vaccines containing one strain from each B lineage in addition to H1N1 and H3N2 strains. However, it is also important to know whether vaccines containing a single influenza B strain can provide cross-protectivity against viruses of the antigenically distinct lineage. The aim of this study was to assess in naïve ferrets the potential cross-protective activity of trivalent live attenuated influenza vaccine (T-LAIV) against challenge with a heterologous wild-type influenza B virus belonging to the genetically different lineage and to compare this activity with effectiveness of quadrivalent LAIV (Q-LAIV) in the ferret model. METHODS AND RESULTS: Ferrets were vaccinated with either one dose of trivalent LAIV containing B/Victoria or B/Yamagata lineage virus, or quadrivalent LAIV (containing both B lineages), or placebo. They were then challenged with B/Victoria or B/Yamagata lineage wild-type virus 28 days after vaccination. The ferrets were monitored for clinical signs and morbidity. Nasal swabs and lung tissue samples were analyzed for the presence of challenge virus. Antibody response to vaccination was assessed by routine hemagglutination inhibition assay. All LAIVs tested were found to be safe and effective against wild-type influenza B viruses based on clinical signs, and virological and histological data. The absence of interference between vaccine strains in trivalent and quadrivalent vaccine formulations was confirmed. Trivalent LAIVs were shown to have the potential to be cross-protective against infection with genetically different influenza B/Victoria and B/Yamagata lineages. CONCLUSIONS: In this ferret model, quadrivalent vaccine provided higher protection to challenge against both B/Victoria and B/Yamagata lineage viruses. However, T-LAIV provided some cross-protection in the case of a mismatch between circulating and vaccine type B strains. Notably, B/Victoria-based T-LAIV was more protective compared to B/Yamagata-based T-LAIV. SN - 1932-6203 UR - https://www.unboundmedicine.com/medline/citation/30507951/Rationale_for_vaccination_with_trivalent_or_quadrivalent_live_attenuated_influenza_vaccines:_Protective_vaccine_efficacy_in_the_ferret_model_ L2 - http://dx.plos.org/10.1371/journal.pone.0208028 DB - PRIME DP - Unbound Medicine ER -